New hope for Tough-to-Treat head & neck cancer: major trial tests powerful drug combo
NCT ID NCT07509099
Summary
This study is for adults with advanced head and neck cancer that has returned or spread. It aims to see if adding the drug cetuximab to a standard treatment of immunotherapy and chemotherapy is more effective at controlling the cancer and helping patients live longer. About 316 participants will be randomly assigned to receive either the new combination or the standard treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.